

Pharmaceutical Management Agency  
New Zealand  
Pharmaceutical Schedule

# Section H Update

for Hospital Pharmaceuticals

**August 2020**

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white and grey wavy lines on a grey background.

**PHARMAC**  
TE PĀTAKA WHAIORANGA

# Contents

Summary of decisions effective 1 August 2020.....	3
Section H changes to Part II .....	7
Index.....	16

## Summary of decisions

EFFECTIVE 1 AUGUST 2020

- Adalimumab inj 20 mg per 0.4 ml syringe and inj 40 mg per 0.8 ml syringe (Humira) and inj 40 mg per 0.8 ml pen (HumiraPen) – amended restriction criteria
- Alfentanil (Hameln) inj 0.5 mg per ml, 2 ml ampoule – price decrease and addition of HSS
- Allopurinol (DP-Allopurinol) tab 100 mg and 300 mg – price increase and addition of HSS
- Amoxicillin grans for oral liq 125 mg per 5 ml (Alphamox 125) and grans for oral liq 250 mg per 5 ml (Alphamox 250) – price increase and addition of HSS
- Amoxicillin with clavulanic acid (Augmentin) grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml – price increase
- Benzylpenicillin sodium [penicillin g] (Sandoz) inj 600 mg (1 million units) vial – price increase and addition of HSS
- Benzylpenicillin sodium [penicillin g] inj 600 mg (1 million units) vial (Pan-Penicillin G Sodium and Sandoz, 100 inj pack) – to be delisted 1 November 2020
- Betahistine dihydrochloride (Vergo 16) tab 16 mg – price increase and addition of HSS
- Bupivacaine hydrochloride with fentanyl inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag; inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml and 20 ml syringe (Biomed) and inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml and 200 ml bag (Bupafen) – new pack size listing
- Cefazolin (AFT) inj 500 mg vial – addition of HSS
- Cefazolin (AFT) inj 1 g vial – price increase and addition of HSS
- Cefotaxime (DBL Cefotaxime) inj 1 g vial – price increase and addition of HSS
- Chlorhexidine soln 4% – new listing
- Chlorhexidine with ethanol soln 0.5% with ethanol 70% and 2% with ethanol 70% – new listing
- Ciprofloxacin (Ciprox) tab 250 mg, 500 mg and 750 mg – price increase and addition of HSS
- Cladribine (Leustatin) inj 1 mg per ml, 10 ml vial – new pack size listing
- Clonidine (Mylan) patch 2.5 mg, 100 mcg per day, patch 5 mg, 200 mcg per day and patch 7.5 mg, 300 mcg per day – price increase and addition of HSS
- Codeine phosphate (PSM) tab 15 mg, 30 mg and 60 mg – price increase and addition of HSS

## Summary of decisions – effective 1 August 2020 (continued)

- Desmopressin acetate (Desmopressin-PH&T) nasal spray 10 mcg per dose, 6 ml – price increase and addition of HSS
  - Etanercept (Enbrel) inj 25 mg vial and inj 50 mg autoinjector and syringe – amended restriction criteria
  - Fentanyl (Biomed) inj 10 mcg per ml, 100 ml bag – new pack size listing
  - Flucloxacillin (Flucil) inj 1 g vial – price increase and addition of HSS
  - Fluconazole (Mylan) cap 50 mg, 150 mg and 200 mg – price increase and addition of HSS
  - Fosfomycin (e.g. UroFos) powder for oral solution, 3 g sachet – addition of example brand
  - Gemfibrozil (Lipazil) tab 600 mg – restrictions added and to be delisted 1 January 2021
  - Gliclazide (Glizide) tab 80 mg – price increase and addition of HSS
  - Glucose [dextrose] (Biomed) inj 50%, 10 ml ampoule and 90 ml bottle – price increase and addition of HSS
  - Hydrocortisone (Hydrocortisone (PSM)) crm 1%, 500 g – amended brand name
  - Indapamide (Dapa-Tabs) tab 2.5 mg – price increase and addition of HSS
  - Infliximab (Remicade) inj 100 mg – addition of HSS and amended restriction criteria
  - Iodine with ethanol soln 1% with ethanol 70% – new listing
  - Isosorbide mononitrate tab 20 mg (Ismo-20) and tab long-acting 60 mg (Duride) – price increase and addition of HSS
  - Isosorbide mononitrate (Ismo 40 Retard) tab long-acting 40 mg – addition of HSS
  - Ispaghula (psyllium) husk (Konsyl-D) powder for oral soln, 500 g – price increase and addition of HSS
  - Ketamine (Biomed) inj 1 mg per ml, 100 ml bag – new pack size listing
  - Ketoconazole (Sebizole) shampoo 2%, 100 ml – price increase and addition of HSS
  - Lamivudine (Lamivudine Alphapharm) tab 150 mg – new listing and addition of HSS
  - Lamivudine (Zetlam) tab 100 mg – price increase and addition of HSS
  - Lamotrigine (Arrow-Lamotrigine) tab dispersible 5 mg – to be delisted 1 October 2020
  - Metaraminol (Torbay) inj 10 mg per ml, 1 ml ampoule – new listing and addition of HSS
-

## Summary of decisions – effective 1 August 2020 (continued)

- Miconazole nitrate (Micreme) vaginal crm 2% with applicator, 40 g – price increase and addition of HSS
  - Mitomycin C (Omegapharm) inj 20 mg vial – to be delisted 1 November 2020
  - Morphine sulphate (Sevredol) tab immediate-release 10 mg and 20 mg – addition of HSS
  - Morphine sulphate (Biomed) inj 1 mg per ml, 10 ml and 50 ml syringe and 100 ml bag – price increase and addition of HSS
  - Olanzapine tab 2.5 mg, 5 mg and 10 mg (Zypine) and tab orodispersible 5 mg and 10 mg (Zypine ODT) – price increase and addition of HSS
  - Paclitaxel (Paclitaxel Ebewe) inj 6 mg per ml, 16.7 ml and 50 mg vial – price increase and addition of HSS
  - Paracetamol oral liq 120 mg per 5 ml (Paracare), oral liq 250 mg per 5 ml (Paracare Double Strength), 1,000 ml and inj 10 mg per ml, 100 ml vial (Paracetamol Kabi) – price increase and addition of HSS
  - Pegaspargase (Oncaspar LYO) inj 750 iu per ml, 5 ml vial – price increase
  - Peptide-based enteral feed 1 kcal/ml (e.g. Nutrison Advanced Peptisorb) liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag – new listing
  - Peptide-based enteral feed 1 kcal/ml (e.g. Nutrison Advanced Peptisorb) liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag – to be delisted 1 February 2021
  - Permethrin crm 5%, 30 g (Lyderm) and lotn 5%, 30 ml (A-Scabies) – price increase and addition of HSS
  - Pine tar with trolamine laurilsulfate and fluorescein (Pinetarsol) soln 2.3% with trolamine laurilsulfate and fluorescein sodium, 500 ml – price increase and addition of HSS
  - Poloxamer (Coloxy) oral drops 10%, 30 ml – price increase and addition of HSS
  - Quetiapine (Quetapel) tab 25 mg, 100 mg, 200 mg and 300 mg – price increase and addition of HSS
  - Ranitidine (Ranitidine Relief) tab 150 mg and 300 mg – to be delisted 1 October 2020
  - Ranitidine (Zantac) inj 25 mg per ml 2 ml ampoule – to be delisted 1 March 2021
  - Rifampicin (Rifadin) cap 150 mg, 300 mg, oral liq 100 mg per 5 ml and inj 600 mg vial – price increase and addition of HSS
  - Risperidone (Risperon) oral liq 1 mg per ml, 30 ml – price increase and addition of HSS
-

## Summary of decisions – effective 1 August 2020 (continued)

- Ropivacaine hydrochloride (Ropivacaine Kabi) inj 2 mg per ml, 10 ml and 20 ml ampoule; inj 2 mg per ml, 100 ml and 200 ml bag; inj 7.5 mg per ml, 10 ml and 20 ml ampoule and inj 10 mg per ml, 10 ml and 20 ml ampoule – price increase and addition of HSS
- Simvastatin (Simvastatin Mylan) tab 10 mg, 20 mg, 40 mg and 80 mg – price increase and addition of HSS
- Tamoxifen citrate (Tamoxifen Sandoz) tab 10 mg and 20 mg – price increase and addition of HSS
- Temazepam (Normison) tab 10 mg – price increase and addition of HSS
- Tramadol hydrochloride (Tramal SR 100) tab sustained-release 100 mg – price decrease and addition of HSS
- Tramadol hydrochloride tab sustained-release 150 mg (Tramal SR 150) and tab sustained-release 200 mg (Tramal SR 200) – addition of HSS
- Triamcinolone acetonide (Kenalog in Orabase) paste 0.1%, 5 g – addition of HSS
- Triamcinolone acetonide (Aristocort) crm 0.02% and oint 0.02%, 100 g – addition of HSS
- Triamcinolone acetonide inj 10 mg per ml, 1 ml ampoule (Kenacort-A 10) and inj 40 mg per ml, 1 ml ampoule (Kenacort-A 40) – addition of HSS

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

## Section H changes to Part II

Effective 1 August 2020

### ALIMENTARY TRACT AND METABOLISM

8	RANITIDINE (delisting)			
	→ Tab 150 mg .....	12.91	500	Ranitidine Relief
	→ Tab 300 mg .....	18.21	500	Ranitidine Relief
	Note – Ranitidine Relief tab 150 mg and 300 mg to be delisted from 1 October 2020.			
8	RANITIDINE (delisting)			
	→ Inj 25 mg per ml, 2 ml ampoule.....	13.40	5	Zantac
	Note – Zantac inj 25 mg per ml, 2 ml ampoule to be delisted from 1 March 2021.			
10	GLICLAZIDE (↑ price and addition of HSS)			
	Tab 80 mg – <b>1% DV Nov-20 to 2023</b> .....	15.18	500	Glizide
12	POLOXAMER (↑ price and addition of HSS)			
	Oral drops 10% – <b>1% DV Nov-20 to 2023</b> .....	3.98	30 ml	Coloxyl
12	ISPAGHULA (PSYLLIUM) HUSK (↑ price and addition of HSS)			
	Powder for oral soln – <b>1% DV Nov-20 to 2023</b> .....	12.20	500 g	Konsyl-D
19	TRIAMCINOLONE ACETONIDE (addition of HSS)			
	Paste 0.1% – <b>1% DV Nov-20 to 2023</b> .....	5.33	5 g	Kenalog in Orabase

### BLOOD AND BLOOD FORMING ORGANS

35	GLUCOSE [DEXTROSE] (↑ price and addition of HSS)			
	Inj 50%, 10 ml ampoule – <b>1% DV Nov-20 to 2023</b> .....	30.65	5	Biomed
	Inj 50%, 90 ml bottle – <b>1% DV Nov-20 to 2023</b> .....	15.00	1	Biomed

### CARDIOVASCULAR SYSTEM

43	CLONIDINE (↑ price and addition of HSS)			
	Patch 2.5 mg, 100 mcg per day – <b>1% DV Nov-20 to 2023</b> .....	10.34	4	Mylan
	Patch 5 mg, 200 mcg per day – <b>1% DV Nov-20 to 2023</b> .....	13.18	4	Mylan
	Patch 7.5 mg, 300 mcg per day – <b>1% DV Nov-20 to 2023</b> .....	16.93	4	Mylan
45	INDAPAMIDE (↑ price and addition of HSS)			
	Tab 2.5 mg – <b>1% DV Nov-20 to 2023</b> .....	10.45	90	Dapa-Tabs
45	GEMFIBROZIL – <b>Restricted: For continuation only</b> (restriction added and delisting)			
	Tab 600 mg .....	19.56	60	Lipazil
	Note – Lipazil tab 600 mg to be delisted from 1 January 2021.			
45	SIMVASTATIN (↑ price and addition of HSS)			
	Tab 10 mg – <b>1% DV Nov-20 to 2023</b> .....	1.23	90	Simvastatin Mylan
	Tab 20 mg – <b>1% DV Nov-20 to 2023</b> .....	2.03	90	Simvastatin Mylan
	Tab 40 mg – <b>1% DV Nov-20 to 2023</b> .....	3.58	90	Simvastatin Mylan
	Tab 80 mg – <b>1% DV Nov-20 to 2023</b> .....	7.12	90	Simvastatin Mylan

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 August 2020 (continued)

46	ISOSORBIDE MONONITRATE (↑ price and addition of HSS) Tab 20 mg – <b>1% DV Nov-20 to 2023</b> ..... 19.55	100		<b>Ismo-20 Duride</b>
	Tab long-acting 60 mg – <b>1% DV Nov-20 to 2023</b> ..... 9.25	90		
46	ISOSORBIDE MONONITRATE (addition of HSS) Tab long-acting 40 mg – <b>1% DV Nov-20 to 2023</b> ..... 8.20	30		<b>Ismo 40 Retard</b>
47	METARAMINOL (new listing and addition of HSS) Inj 10 mg per ml, 1 ml ampoule – <b>1% DV Jan-21 to 2023</b> ..... 55.20	10		<b>Torbay</b>

## DERMATOLOGICALS

52	KETOCONAZOLE (↑ price and addition of HSS) Shampoo 2% – <b>1% DV Nov-20 to 2023</b> ..... 3.23	100 ml		<b>Sebizole</b>
53	PERMETHRIN (↑ price and addition of HSS) Crn 5% – <b>1% DV Nov-20 to 2023</b> ..... 5.75	30 g		<b>Lyderm A-Scabies</b>
	Lotn 5% – <b>1% DV Nov-20 to 2023</b> ..... 3.99	30 ml		
55	HYDROCORTISONE (amended brand name) Crn 1%, 500 g ..... 17.15	500 g		<b>Hydrocortisone (PSM) Pharmacy Health</b>
56	TRIAMCINOLONE ACETONIDE (addition of HSS) Crn 0.02% – <b>1% DV Nov-20 to 2023</b> ..... 6.30	100 g		<b>Aristocort Aristocort</b>
	Oint 0.02% – <b>1% DV Nov-20 to 2023</b> ..... 6.35	100 g		
56	PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIEIN (↑ price and addition of HSS) Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – <b>1% DV Nov-20 to 2023</b> ..... 4.44	500 ml		<b>Pinetarsol</b>

## GENITO-URINARY SYSTEM

58	MICONAZOLE NITRATE (↑ price and addition of HSS) Vaginal crn 2% with applicator – <b>1% DV Nov-20 to 2023</b> ..... 6.89	40 g		<b>Micreme</b>
----	---	------	--	----------------

## HORMONE PREPARATIONS

64	TRIAMCINOLONE ACETONIDE (addition of HSS) Inj 10 mg per ml, 1 ml ampoule – <b>5% DV Nov-20 to 2023</b> ..... 20.80	5		<b>Kenacort-A 10 Kenacort-A 40</b>
	Inj 40 mg per ml, 1 ml ampoule – <b>1% DV Nov-20 to 2023</b> ..... 51.10	5		
71	DESMOPRESSIN ACETATE (↑ price and addition of HSS) Nasal spray 10 mcg per dose – <b>1% DV Nov-20 to 2023</b> ..... 27.95	6 ml		<b>Desmopressin-PH&amp;T</b>

## INFECTIONS

73	CEFAZOLIN (addition of HSS) Inj 500 mg vial – <b>1% DV Nov-20 to 2023</b> ..... 3.39	5		<b>AFT</b>
----	---	---	--	------------

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.



		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
<b>Changes to Section H Part II – effective 1 August 2020 (continued)</b>			
73	CEFAZOLIN (↑ price and addition of HSS) Inj 1 g vial – <b>1% DV Nov-20 to 2023</b> .....	3.49 5	<b>AFT</b>
73	CEFOTAXIME (↑ price and addition of HSS) Inj 1 g vial – <b>1% DV Nov-20 to 2023</b> .....	45.00 10	<b>DBL Cefotaxime</b>
76	AMOXICILLIN (↑ price and addition of HSS) Grans for oral liq 125 mg per 5 ml – <b>1% DV Nov-20 to 2023</b> .....	1.40 100 ml	<b>Alphamox 125</b>
	Grans for oral liq 250 mg per 5 ml – <b>1% DV Nov-20 to 2023</b> .....	1.73 100 ml	<b>Alphamox 250</b>
76	AMOXICILLIN WITH CLAVULANIC ACID (↑ price) Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml.....	5.00 100 ml	Augmentin
76	BENZYLPENICILLIN SODIUM [PENICILLIN G] (↑ price and addition of HSS) Inj 600 mg (1 million units) vial – <b>1% DV Nov-20 to 2023</b> .....	11.09 10	<b>Sandoz</b>
76	BENZYLPENICILLIN SODIUM [PENICILLIN G] (delisting) Inj 600 mg (1 million units) vial.....	25.88 25	Pan-Penicillin G Sodium
		103.50 100	Sandoz
	Note – Pan-Penicillin G Sodium and Sandoz inj 600 mg (1 million units) vial, 100 inj pack to be delisted from 1 November 2020.		
76	FLUCLOXACILLIN (↑ price and addition of HSS) Inj 1 g vial – <b>1% DV Nov-20 to 2023</b> .....	5.70 5	<b>Flucil</b>
77	CIPROFLOXACIN (↑ price and addition of HSS) → Tab 250 mg – <b>1% DV Nov-20 to 2023</b> .....	2.42 28	<b>Cipflox</b>
	→ Tab 500 mg – <b>1% DV Nov-20 to 2023</b> .....	3.40 28	<b>Cipflox</b>
	→ Tab 750 mg – <b>1% DV Nov-20 to 2023</b> .....	5.95 28	<b>Cipflox</b>
78	FOSFOMYCIN (addition of example brand) → Powder for oral solution, 3 g sachet		<i>e.g. UroFos</i>
80	FLUCONAZOLE (↑ price and addition of HSS) → Cap 50 mg – <b>1% DV Nov-20 to 2023</b> .....	2.75 28	<b>Mylan</b>
	→ Cap 150 mg – <b>1% DV Nov-20 to 2023</b> .....	0.65 1	<b>Mylan</b>
	→ Cap 200 mg – <b>1% DV Nov-20 to 2023</b> .....	12.89 28	<b>Mylan</b>
83	RIFAMPICIN (↑ price and addition of HSS) → Cap 150 mg – <b>1% DV Nov-20 to 2023</b> .....	58.54 100	<b>Rifadin</b>
	→ Cap 300 mg – <b>1% DV Nov-20 to 2023</b> .....	122.06 100	<b>Rifadin</b>
	→ Oral liq 100 mg per 5 ml – <b>1% DV Nov-20 to 2023</b> .....	12.60 60 ml	<b>Rifadin</b>
	→ Inj 600 mg vial – <b>1% DV Nov-20 to 2023</b> .....	134.98 1	<b>Rifadin</b>

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 August 2020 (continued)

86	LAMIVUDINE (new listing and addition of HSS) → Tab 150 mg – <b>1% DV Nov-20 to 2023</b> .....	84.50	60	<b>Lamivudine Alphapharm</b>
	Restricted Initiation – Confirmed HIV Patient has confirmed HIV infection. Initiation – Prevention of maternal transmission Either: 1 Prevention of maternal foetal transmission; or 2 Treatment of the newborn for up to eight weeks. Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV Both: 1 Treatment course to be initiated within 72 hours post exposure; and 2 Any of the following: 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required. Initiation – Percutaneous exposure Patient has percutaneous exposure to blood known to be HIV positive.			

88	LAMIVUDINE (↑ price and addition of HSS) Tab 100 mg – <b>1% DV Nov-20 to 2023</b> .....	6.95	28	<b>Zetlam</b>
----	--	------	----	---------------

## MUSCULOSKELETAL SYSTEM

100	ALLOPURINOL (↑ price and addition of HSS) Tab 100 mg – <b>1% DV Nov-20 to 2023</b> .....	11.47	500	<b>DP-Allopurinol</b>
	Tab 300 mg – <b>1% DV Nov-20 to 2023</b> .....	28.57	500	<b>DP-Allopurinol</b>

## NERVOUS SYSTEM

105	KETAMINE (pack size change) Inj 1 mg per ml, 100 ml bag – <b>1% DV Feb-20 to 2022</b> .....	135.00	5	<b>Biomed</b>
	Note – Biomed inj 1 mg per ml, 100 ml bag, 10 inj pack to be delisted from 1 November 2020.			
106	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (pack size change) Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag – <b>1% DV Apr-20 to 2022</b> .....	152.50	5	<b>Biomed</b>
	Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – <b>1% DV Nov-19 to 2022</b> .....	112.50	5	<b>Bupafen</b>
	Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – <b>1% DV Nov-19 to 2022</b> .....	117.50	5	<b>Bupafen</b>
	Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe .....	36.00	5	<b>Biomed</b>
	Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe .....	46.00	5	<b>Biomed</b>
	Note – Biomed inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag; inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml and 20 ml syringe, 10 inj pack and Bupafen inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml and 200 ml bag, 10 inj pack to be delisted from 1 November 2020.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer	
<b>Changes to Section H Part II – effective 1 August 2020 (continued)</b>				
108	ROPIVACAINE HYDROCHLORIDE (↑ price and addition of HSS)			
	Inj 2 mg per ml, 10 ml ampoule – 1% DV Nov-20 to 2023 .....	9.25	5	<b>Ropivacaine Kabi</b>
	Inj 2 mg per ml, 20 ml ampoule – 1% DV Nov-20 to 2023 .....	9.65	5	<b>Ropivacaine Kabi</b>
	Inj 2 mg per ml, 100 ml bag – 1% DV Nov-20 to 2023 .....	31.00	5	<b>Ropivacaine Kabi</b>
	Inj 2 mg per ml, 200 ml bag – 1% DV Nov-20 to 2023 .....	40.95	5	<b>Ropivacaine Kabi</b>
	Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Nov-20 to 2023 .....	10.40	5	<b>Ropivacaine Kabi</b>
	Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Nov-20 to 2023 .....	12.75	5	<b>Ropivacaine Kabi</b>
	Inj 10 mg per ml, 10 ml ampoule – 1% DV Nov-20 to 2023 .....	11.10	5	<b>Ropivacaine Kabi</b>
	Inj 10 mg per ml, 20 ml ampoule – 1% DV Nov-20 to 2023 .....	16.60	5	<b>Ropivacaine Kabi</b>
109	PARACETAMOL (↑ price and addition of HSS)			
	Oral liq 120 mg per 5 ml – 20% DV Nov-20 to 2023 .....	5.45	1,000 ml	<b>Paracare</b>
	Oral liq 250 mg per 5 ml – 20% DV Nov-20 to 2023 .....	6.25	1,000 ml	<b>Paracare Double Strength</b>
	➔ Inj 10 mg per ml, 100 ml vial – 1% DV Nov-20 to 2023 .....	8.90	10	<b>Paracetamol Kabi</b>
109	ALFENTANIL (↓ price and addition of HSS)			
	Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Nov-20 to 2023 .....	24.75	10	<b>Hameln</b>
109	CODEINE PHOSPHATE (↑ price and addition of HSS)			
	Tab 15 mg – 1% DV Nov-20 to 2023 .....	6.25	100	<b>PSM</b>
	Tab 30 mg – 1% DV Nov-20 to 2023 .....	7.45	100	<b>PSM</b>
	Tab 60 mg – 1% DV Nov-20 to 2023 .....	14.25	100	<b>PSM</b>
109	FENTANYL (pack size change)			
	Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022 .....	110.00	5	<b>Biomed</b>
	Note – Biomed inj 10 mcg per ml, 100 ml bag, 10 inj pack to be delisted from 1 November 2020.			
110	MORPHINE SULPHATE (addition of HSS)			
	Tab immediate-release 10 mg – 1% DV Nov-20 to 2023 .....	2.80	10	<b>Sevredol</b>
	Tab immediate-release 20 mg – 1% DV Nov-20 to 2023 .....	5.52	10	<b>Sevredol</b>
110	MORPHINE SULPHATE (↑ price and addition of HSS)			
	Inj 1 mg per ml, 100 ml bag – 1% DV Nov-20 to 2023 .....	102.25	5	<b>Biomed</b>
	Inj 1 mg per ml, 10 ml syringe – 1% DV Nov-20 to 2023 .....	24.50	5	<b>Biomed</b>
	Inj 1 mg per ml, 50 ml syringe – 1% DV Nov-20 to 2023 .....	52.00	5	<b>Biomed</b>
111	TRAMADOL HYDROCHLORIDE (↓ price and addition of HSS)			
	Tab sustained-release 100 mg – 1% DV Nov-20 to 2023 .....	1.52	20	<b>Tramal SR 100</b>
111	TRAMADOL HYDROCHLORIDE (addition of HSS)			
	Tab sustained-release 150 mg – 1% DV Nov-20 to 2023 .....	2.10	20	<b>Tramal SR 150</b>
	Tab sustained-release 200 mg – 1% DV Nov-20 to 2023 .....	2.75	20	<b>Tramal SR 200</b>
114	LAMOTRIGINE (delisting)			
	Tab dispersible 5 mg .....	15.00	56	<b>Arrow-Lamotrigine</b>
	Note – Arrow-Lamotrigine tab dispersible 5 mg to be delisted from 1 October 2020.			
117	BETAHISTINE DIHYDROCHLORIDE (↑ price and addition of HSS)			
	Tab 16 mg – 1% DV Nov-20 to 2023 .....	3.88	84	<b>Vergo 16</b>

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 August 2020 (continued)

119	OLANZAPINE (↑ price and addition of HSS)			
	Tab 2.5 mg – 1% DV Nov-20 to 2023 .....	1.35	28	Zypine
	Tab 5 mg – 1% DV Nov-20 to 2023 .....	1.58	28	Zypine
	Tab orodispersible 5 mg – 1% DV Nov-20 to 2023 .....	1.81	28	Zypine ODT
	Tab 10 mg – 1% DV Nov-20 to 2023 .....	2.01	28	Zypine
	Tab orodispersible 10 mg – 1% DV Nov-20 to 2023 .....	2.38	28	Zypine ODT
119	QUETIAPINE (↑ price and addition of HSS)			
	Tab 25 mg – 1% DV Nov-20 to 2023 .....	2.15	90	Quetapel
	Tab 100 mg – 1% DV Nov-20 to 2023 .....	5.06	90	Quetapel
	Tab 200 mg – 1% DV Nov-20 to 2023 .....	8.90	90	Quetapel
	Tab 300 mg – 1% DV Nov-20 to 2023 .....	12.86	90	Quetapel
119	RISPERIDONE (↑ price and addition of HSS)			
	Oral liq 1 mg per ml – 1% DV Nov-20 to 2023 .....	8.90	30 ml	Risperon
123	TEMAZEPAM (↑ price and addition of HSS)			
	Tab 10 mg – 1% DV Nov-20 to 2023 .....	1.33	25	Normison

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

131	MITOMYCIN C (delisting)			
	Inj 20 mg vial .....	816.32	1	Omegapharm
	Note – Omegapharm inj 20 mg vial to be delisted from 1 November 2020.			
131	CLADRIBINE (pack size change)			
	Inj 1 mg per ml, 10 ml vial .....	749.96	1	Leustatin
	Note – Leustatin inj 1 mg per ml, 10 ml vial, 7 inj pack to be delisted from 1 October 2020.			
135	PEGASPARGASE (↑ price)			
	→ Inj 750 iu per ml, 5 ml vial .....	3,455.00	1	Oncaspar LYO
145	PACLITAXEL (↑ price and addition of HSS)			
	Inj 6 mg per ml, 16.7 ml vial – 1% DV Nov-20 to 2023 .....	24.00	1	Paclitaxel Ebewe
	Inj 6 mg per ml, 50 ml vial – 1% DV Nov-20 to 2023 .....	44.00	1	Paclitaxel Ebewe
149	TAMOXIFEN CITRATE (↑ price and addition of HSS)			
	Tab 10 mg – 1% DV Nov-20 to 2023 .....	15.00	60	Tamoxifen Sandoz
	Tab 20 mg – 1% DV Nov-20 to 2023 .....	6.65	60	Tamoxifen Sandoz

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 August 2020 (continued)

150	ETANERCEPT (amended restriction criteria – affected criteria shown only)			
	→ Inj 25 mg vial – 5% DV Sep-19 to 2024 .....	690.00	4	<b>Enbrel</b>
	→ Inj 50 mg autoinjector – 5% DV Sep-19 to 2024 .....	1,050.00	4	<b>Enbrel</b>
	→ Inj 50 mg syringe – 5% DV Sep-19 to 2024 .....	1,050.00	4	<b>Enbrel</b>
	Restricted			
	Initiation – pyoderma gangrenosum			
	Dermatologist			
	All of the following:			
	1 Patient has pyoderma gangrenosum*; and			
	2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and			
	3 A maximum of <b>8 4</b> -doses.			
	Note: Indications marked with * are unapproved indications.			
	Continuation – pyoderma gangrenosum			
	Dermatologist			
	All of the following:			
	1 Patient has shown clinical improvement; and			
	2 Patient continues to require treatment; and			
	3 A maximum of <b>8 4</b> -doses.			
156	ADALIMUMAB (amended restriction criteria – affected criteria shown only)			
	→ Inj 20 mg per 0.4 ml syringe .....	1,599.96	2	Humira
	→ Inj 40 mg per 0.8 ml pen .....	1,599.96	2	HumiraPen
	→ Inj 40 mg per 0.8 ml syringe .....	1,599.96	2	Humira
	Restricted			
	Initiation – pyoderma gangrenosum			
	Dermatologist			
	All of the following:			
	1 Patient has pyoderma gangrenosum*; and			
	2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and			
	3 A maximum of <b>8 4</b> -doses.			
	Note: Indications marked with * are unapproved indications.			
	Continuation – pyoderma gangrenosum			
	Dermatologist			
	All of the following:			
	1 Patient has shown clinical improvement; and			
	2 Patient continues to require treatment; and			
	3 A maximum of <b>8 4</b> -doses.			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 August 2020 (continued)

168 INFLIXIMAB (addition of HSS and amended restrictions – affected and new criteria shown only)

➔ Inj 100 mg – 5% DV Sep-20 to 2024 ..... 806.00 1 **Remicade**

Restricted

Initiation – plaque psoriasis

Dermatologist

*Re-assessment required after 3 doses*

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or

1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or

2 All of the following:

2.1 Either:

2.1.1 Patient has “whole body” severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than **10 +5**, where lesions have been present for at least 6 months from the time of initial diagnosis; or

2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: “Inadequate response” is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than **10 +5**, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Initiation - pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum\*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 8 doses.

Note: Indications marked with \* are unapproved indications.

**Continuation – pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has shown clinical improvement; and

2 Patient continues to require treatment; and

3 A maximum of 8 doses.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

## Changes to Section H Part II – effective 1 August 2020 (continued)

### VARIOUS

- 223 CHLORHEXIDINE (new listing)  
Soln 4%
- 223 CHLORHEXIDINE WITH ETHANOL (new listing)  
Soln 0.5% with ethanol 70%  
Soln 2% with ethanol 70%
- 223 IODINE WITH ETHANOL (new listing)  
Soln 1% with ethanol 70%

### SPECIAL FOODS

- 238 PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML (new listing)  
→ Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g  
fat per 100 ml, 1,000 ml bag *e.g. Nutrison Advanced  
Peptisorb*
- 238 PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML (delisting)  
→ Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g  
fat per 100 ml, 1,000 ml bag *e.g. Nutrison Advanced  
Peptisorb*
- Note – e.g. Nutrison Advanced Peptisorb liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag to be delisted 1 February 2021.

# Index

## Pharmaceuticals and brands

<b>A</b>	
Adalimumab.....	13
Alfentanil.....	11
Allopurinol.....	10
Alphamox 125.....	9
Alphamox 250.....	9
Amoxicillin.....	9
Amoxicillin with clavulanic acid.....	9
Aristocort.....	8
Arrow-Lamotrigine.....	11
A-Scabies.....	8
Augmentin.....	9
<b>B</b>	
Benzylpenicillin sodium [Penicillin G].....	9
Betahistine dihydrochloride.....	11
Bupafen.....	10
Bupivacaine hydrochloride with fentanyl.....	10
<b>C</b>	
Cefazolin.....	8, 9
Cefotaxime.....	9
Chlorhexidine.....	15
Chlorhexidine with ethanol.....	15
Cipflox.....	9
Ciprofloxacin.....	9
Cladribine.....	12
Clonidine.....	7
Codeine phosphate.....	11
Coloxyl.....	7
<b>D</b>	
Dapa-Tabs.....	7
DBL Cefotaxime.....	9
Desmopressin acetate.....	8
Desmopressin-PH&T.....	8
Dextrose.....	7
DP-Allopurinol.....	10
Duride.....	8
<b>E</b>	
Enbrel.....	13
Etanercept.....	13
<b>F</b>	
Fentanyl.....	11
Flucil.....	9
Flucloxacillin.....	9
Fluconazole.....	9
Fosfomycin.....	9
<b>G</b>	
Gemfibrozil.....	7
Gliclazide.....	7
Glizide.....	7
Glucose [Dextrose].....	7
<b>H</b>	
Humira.....	13
HumiraPen.....	13
Hydrocortisone.....	8
Hydrocortisone (PSM).....	8
<b>I</b>	
Indapamide.....	7
Infliximab.....	14
Iodine with ethanol.....	15
Ismo-20.....	8
Ismo 40 Retard.....	8
Isosorbide mononitrate.....	8
Ispaghula (psyllium) husk.....	7
<b>K</b>	
Kenacort-A 10.....	8
Kenacort-A 40.....	8
Kenalog in Orabase.....	7
Ketamine.....	10
Ketoconazole.....	8
Konsyl-D.....	7
<b>L</b>	
Lamivudine.....	10
Lamivudine Alphapharm.....	10
Lamotrigine.....	11
Leustatin.....	12
Lipazil.....	7
Lyderm.....	8
<b>M</b>	
Metaraminol.....	8
Miconazole nitrate.....	8
Micreme.....	8
Mitomycin C.....	12
Morphine sulphate.....	11
<b>N</b>	
Normison.....	12
Nutrison Advanced Peptisorb.....	15
<b>O</b>	
Olanzapine.....	12
Omegapharm.....	12
Oncaspar LYO.....	12
<b>P</b>	
Paclitaxel.....	12
Paclitaxel Ebewe.....	12
Pan-Penicillin G Sodium.....	9
Paracare.....	11
Paracare Double Strength.....	11
Paracetamol.....	11
Paracetamol Kabi.....	11
Pegaspargase.....	12
Penicillin G.....	9
Peptide-based enteral feed 1 kcal/ml.....	15



# Index

## Pharmaceuticals and brands

Permethrin .....	8	Simvastatin Mylan .....	7
Pinetarsol.....	8	<b>T</b>	
Pine tar with trolamine laurilsulfate and fluorescein..	8	Tamoxifen citrate.....	12
Poloxamer .....	7	Tamoxifen Sandoz.....	12
<b>Q</b>		Temazepam .....	12
Quetapel .....	12	Torbay .....	8
Quetiapine.....	12	Tramadol hydrochloride.....	11
<b>R</b>		Tramal SR 100.....	11
Ranitidine.....	7	Tramal SR 150.....	11
Ranitidine Relief .....	7	Tramal SR 200.....	11
Remicade .....	14	Triamcinolone acetonide .....	7, 8
Rifadin .....	9	<b>U</b>	
Rifampicin .....	9	UroFos.....	9
Risperidone.....	12	<b>V</b>	
Risperon.....	12	Vergo 16.....	11
Ropivacaine hydrochloride .....	11	<b>Z</b>	
Ropivacaine Kabi .....	11	Zantac.....	7
<b>S</b>		Zetlam .....	10
Sebizole.....	8	Zypine.....	12
Sevredol .....	11	Zypine ODT .....	12
Simvastatin.....	7		

New Zealand  
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand